Collaboration among research scientists, physicians, industry, and patients is essential for the advancement of treatments for human diseases, as each of these stakeholders contributes a unique and valuable perspective.
Scientists research and develop new theories and technologies,
Physicians apply that knowledge in clinical practice and provide insights into the real needs of patients.
Industry, in turn, plays a crucial role in producing and delivering the achieved advances to the end user, ensuring they are accessible and effective.
Finally, patients are at the center of this entire process; the samples collected from their tissues—be it saliva, blood, or other cells—along with their experiences and feedback, are essential for guiding research and the development of breakthroughs that truly improve their quality of life.
Together, they form an interconnected ecosystem that drives innovation and improves health outcomes.
“The creation of the EIA sample biobank is a very important milestone in the research of this condition.”
For several decades now, genetic and epigenetic theories related to the development of idiopathic scoliosis have gained traction, and this type of initiative brings us closer to a clearer future, where clinicians can make better decisions.
From the Association, we express our commitment to research and thank EpiDisease and the Ciberer Biobank for their role, hoping this will be the beginning of new research lines to improve the quality of life of patients with idiopathic scoliosis.”